| Name | Title | Contact Details |
|---|
Taranis is a leading precision agriculture intelligence platform that uses sophisticated computer vision, data science and deep learning algorithms to effectively monitor fields. Taranis offers a full-stack solution for high precision aerial surveillance imagery to prevent crop yield loss due to insects, crop Farmers lose 30-40% of their yield every season due to crop diseases, insects, and weeds. Our mission: Help growers maximize crop yield, improve productivity, and adopt sustainable practices in order to ensure prosperity, starting in our local communities and for the benefit of the world. Taranis crop intelligence solutions use deep agronomic expertise and the most advanced AI and submillimeter image technologies to do just that. We make an impact for over 100 agribusinesses, thousands of farmers, and in millions of acres around the world, and grow rapidly. Founded in 2015, Taranis raised over $100M from leading VC investors and is being led by a founding team with vast experience in both agriculture and technology.
Breckpoint is dedicated to helping brokers and employers build alternative risk solutions outside of the traditional insurance providers. For employers seeking an alternative to fully-insured group benefit plans or self-insured groups for workers compensation, Breckpoint empowers groups to take advantage of the transparency, control, and underwriting profits generated by high performing self-funded plans. - Self funded benefit administration plans - Self-insured group administration for workers compensation - Captive Management - Risk Management services We believe in Leading Together. This is the essence of Breckpoint. We are here with you through every step of this benefit journey. Your Breckpoint team provides the stellar service you deserve and we look forward to helping you manage your alternative risk programs.
Grenova™ is an innovative company that is revolutionizing lab consumables through high-quality waste reduction solutions. Our mission is to lower costs in the laboratory industry and reduce biohazard waste in the environment by delivering groundbreaking approaches in dealing with plastic consumables. Every year, over 5 million pounds of plastic pipette tips are disposed of in landfills globally after a single use. This drives significant environmental pollution and unnecessary costs. The typical laboratory consumes several thousand pipette tips every day for samples and assay procedures, due to the lack of options for safely cleaning plastic consumables. Such high consumption of plastic tips adds $25,000 to $1.5 million in annual operational costs for laboratories worldwide. At Grenova™, we know that high consumption of plastic tips is an excessive, avoidable operational cost for companies and a significant contributor to environmental pollution. This is why we decided to create devices that enable labs to wash and recycle pipette tips in large quantities. Grenova devices offer labs the option to reuse plastic tips several times, cutting associated costs by up to 90%. Grenova devices are safe for both the user and the environment, without producing hazardous waste or gases.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.